<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262830</url>
  </required_header>
  <id_info>
    <org_study_id>181758</org_study_id>
    <nct_id>NCT04262830</nct_id>
  </id_info>
  <brief_title>Cancer Therapy Effects on the Heart</brief_title>
  <acronym>CTEH</acronym>
  <official_title>Cancer Therapy Effects on the Heart: Identification of Early Markers of Cardiac Disease Progression After Cardiotoxic Childhood Cancer Therapy Using Cardiac Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat
      pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who
      receive these therapies have an increased risk of heart failure and early cardiovascular
      death. However, current strategies for identifying patients who are at risk prior to the
      development of significant changes in heart function are limited. This study will focus on
      imaging markers of cardiac injury and dysfunction with the goal of developing improved
      diagnostic tests and treatment strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat
      pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who
      receive these therapies have an increased risk of heart failure and early cardiovascular
      death. However, current strategies for identifying patients who are at risk prior to the
      development of significant changes in heart function are limited. This study will focus on
      imaging markers of cardiac injury and dysfunction with the goal of developing improved
      diagnostic tests and treatment strategies.

      Cardiac shape, function, and tissue characteristics will be examined using cardiac MRI data
      in combination with standard cardiac assessments (by echocardiography, electrocardiograms,
      and cardiac MRI) to assess the cardiotoxic effects of cancer therapy. Analyses will be
      performed in a cross-sectional cohort of adolescents and young adults with a history of
      childhood cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>2 years</time_frame>
    <description>LVEF is an assessment of left ventricular global systolic function.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Pediatric Cancer</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Clinical Indication for Cardiac MRI</arm_group_label>
    <description>Individuals who are 13-25 years of age with a history of prior cancer treatment, which may include anthracyclines or chest radiation, with clinical indication for cardiac MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Non-Clinically Indicated Cardiac MRI</arm_group_label>
    <description>Individuals who are 13-25 years of age with a history of prior cancer treatment, which may include anthracyclines or chest radiation, without clinical indication for cardiac MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging (MRI)</intervention_name>
    <description>Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics</description>
    <arm_group_label>Cohort 1: Clinical Indication for Cardiac MRI</arm_group_label>
    <arm_group_label>Cohort 2: Non-Clinically Indicated Cardiac MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Echocardiography, heart ultrasound, will be performed in conjunction with cardiac MRI.</description>
    <arm_group_label>Cohort 1: Clinical Indication for Cardiac MRI</arm_group_label>
    <arm_group_label>Cohort 2: Non-Clinically Indicated Cardiac MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Electrocardiogram</intervention_name>
    <description>Measuring conduction abnormalities</description>
    <arm_group_label>Cohort 1: Clinical Indication for Cardiac MRI</arm_group_label>
    <arm_group_label>Cohort 2: Non-Clinically Indicated Cardiac MRI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a cross-sectional cohort of childhood cancer survivors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English and Spanish speaking male and female subjects, ages 14-25 years old

          -  Previously treated for cancer, with diagnosis at least two years prior.

          -  Patients whose cancer has recurred, persisted, is still detectable, or have developed
             a secondary cancer will still be eligible.

        Exclusion Criteria:

          -  Patients who have a contraindication to contrast cardiac MRI, including the presence
             of non-MRI compatible metallic implants and severe renal dysfunction.

          -  Medical, psychiatric, and/or social disorder that would prevent successful completion
             of planned study testing or would preclude the subject from undergoing the cardiac MRI
             without anesthesia.

          -  Patients with a history of congenital heart disease (more significant than a history
             of patent foramen ovale or patent ductus arteriosus).

          -  Patients with orthodontic braces or metallic implants in the thorax or abdomen/lumbar
             spine, even if MRI-compatible, will be excluded as these may cause artifacts and limit
             image quality.

          -  Females who are pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hari Narayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California San Diego, Rady Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hari Narayan, MD</last_name>
    <phone>8589665855</phone>
    <email>hnarayan@rchsd.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danica Griffin, MS</last_name>
    <phone>8585761700</phone>
    <phone_ext>227139</phone_ext>
    <email>dgriffin1@rchsd.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hari Narayan, MD</last_name>
      <phone>858-966-5855</phone>
      <email>hnarayan@rchsd.org</email>
    </contact>
    <contact_backup>
      <last_name>Danica Griffin, MS</last_name>
      <phone>8585761700</phone>
      <phone_ext>227139</phone_ext>
      <email>dgriffin1@rchsd.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hari Narayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis Kuo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin Trovillion, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Hsiao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Omens, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew McCulloch, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danica Griffin, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Abcede, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Hari Narayan, MD</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

